Editor’s Note
**Editor’s Note:** Galderma has raised its full-year revenue targets following a strong first half in 2026, with sales surging 28% to $3.13 billion. The broad-based growth across divisions and regions underscores robust demand for its aesthetic and dermatological products.
Galderma Raises Revenue Targets After Strong First Half
Keystone-SDA
Region Zug
,
23.07.2026 – 09:42
Galderma looks back on a buoyant growth in the first semester of 2026. The growth was broadly based across all divisions and regions, the company announced on Thursday. Against this backdrop, Galderma is also aiming for higher sales in the full year.
The headquarters of Galderma in Zug. – keystone
Between January and June, Galderma generated sales of USD 3.13 billion, an increase of 28.0 percent compared to the previous year. At constant exchange rates, the increase was 24.6 percent, as stated in the communiqué.
The sales increase was attributed to higher sales volumes as well as the product mix. Galderma sells both “injectable aesthetics” such as wrinkle injections and the locally known sunscreen Daylong.
In the aesthetic treatments business, which includes wrinkle treatments with botulinum toxin and dermal fillers, sales increased by 12.1 percent on a currency-adjusted basis to USD 1.4 billion. Growth drivers were primarily the high demand for wrinkle treatments, the introduction of new products, and further market share gains.
In the medical skin care segment, sales increased by 16.4 percent to USD 848 million, driven by strong demand for the Cetaphil and Alastin brands, a rapidly growing e-commerce channel, as well as numerous product innovations and international launches.
The most dynamic development was in the business with prescription drugs for skin diseases, where sales increased by nearly 68 percent to also USD 848 million. The main reason was the successful launch of the drug Nemluvio for inflammatory skin diseases, which already accounted for more than half of the segment’s revenue, while the established dermatology portfolio benefited from a low prior-year base and delayed generic entries.
Galderma increased its operating result before depreciation even more strongly than sales in the reporting period. Core-EBITDA amounted to USD 802 million, up 42.8 percent on a currency-adjusted basis compared to the previous year. The corresponding margin improved by 328 basis points to 25.6 percent. Galderma attributes the increase to sales growth and a favorable timing of operating costs.
With the presented figures, Galderma exceeded the average analyst estimates (AWP consensus).
Against the backdrop of the broadly based business development, Galderma has raised its sales forecast for the full year. The company now expects currency-adjusted sales growth of 19 to 21 percent, compared to the previous 17 to 20 percent. Meanwhile, the core-EBITDA margin for 2026 is still targeted at around 26 percent at constant currencies.
More on the topic:
Dollar
Search keyword: Botulinumtoxin